Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Overview of Immutep Ltd
Immutep Ltd is a globally active biotechnology company committed to advancing immunotherapy for both cancer and autoimmune diseases. Leveraging its expertise in immuno-oncology and innovative LAG-3 technology, the company has positioned itself as a specialized entity in personalized bio-therapeutic products. With dual listings on the Australian Stock Exchange and Nasdaq, Immutep demonstrates a robust international presence and a solid foundation in research and development.
Core Technology and Therapeutic Approach
The hallmark of Immutep’s approach is its focus on the LAG-3 immune control mechanism, a critical regulator of the T cell immune response. By modulating this pathway, Immutep aims to enhance the body’s natural ability to fight cancer and potentially address autoimmune conditions. This technology underpins the company’s strategic pipeline and sets a high standard for clinical precision and targeted therapy development.
Product Pipeline and Clinical Development
Immutep’s product portfolio is centered around its most advanced candidate, IMP321, which functions as a T cell immunostimulatory factor. This therapy is designed for integration into cancer chemoimmunotherapy protocols and has achieved significant clinical milestones in early phase trials. In addition to IMP321, the company is developing IMP701, a blocking anti-LAG-3 antibody candidate in early clinical evaluation, and CVac, a personalized immunocellular strategy under investigation for epithelial cancers. These development efforts illustrate a diverse and forward-looking approach that integrates both innovation and strategic collaboration.
Global Operations and Strategic Collaborations
Operating primarily from Australia, Immutep extends its influence across global markets, supported by strong regulatory compliance and research proficiency. Strategic partnerships with large pharmaceutical firms reinforce its pipeline development, enabling access to advanced clinical platforms and shared expertise. The company’s qualification for significant research tax incentives in both Europe and Australia underscores its commitment to high-caliber R&D and validates the commercial and scientific merits of its initiatives.
Industry Position and Business Model
Within the competitive landscape of biotechnology, Immutep differentiates itself by combining deep scientific expertise with a focused therapeutic strategy. Its business model hinges on collaborative partnerships, clinical innovation, and a targeted approach to harnessing LAG-3 mediated immune modulation. Investors and industry observers appreciate the rigorous clinical frameworks employed by the company, which underpin its potential to offer novel therapeutic modalities in the area of cancer treatment and beyond.
Research and Development Excellence
Immutep’s strategic emphasis on research and development is reflected in its participation in international R&D incentive programs. These initiatives not only provide substantial financial support for its clinical trials but also affirm the company’s adherence to high industry standards and scientific integrity. This relentless focus on innovation is at the core of Immutep’s operational ethos, ensuring that its immunotherapeutic solutions are developed in a rigorous and transparent environment.
Conclusion
In summary, Immutep Ltd stands as a key player in the biotechnology industry, with a specific focus on immunotherapy modalities for cancer and autoimmune diseases. Its reliance on advanced LAG-3 technology, comprehensive product pipeline, and robust global partnerships collectively fortify its standing in the competitive landscape. The company’s commitment to R&D excellence and transparent clinical strategies provides a rich source of insight for those seeking to understand a pioneering approach in modern biotechnology.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has reported encouraging clinical results from its Phase II TACTI-002 trial. The overall response rate (ORR) for the combination therapy of eftilagimod alpha (efti) and KEYTRUDA® in treating first-line non-small cell lung cancer (NSCLC) increased to 40.4%, with notable improvements across all PD-L1 expression groups. Median duration of response was 21.6 months, showing efficacy irrespective of PD-L1 status. The trial, which included 114 patients, demonstrated a favorable safety profile, with only 9.6% discontinuation due to adverse effects.
Immutep Limited (NASDAQ: IMMP) announced promising early results from the INSIGHT-003 trial, evaluating its lead product candidate, eftilagimod alpha (efti), in combination with anti-PD-1 therapy and chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC). The trial reported an Objective Response Rate (ORR) of 72.7% and a Disease Control Rate (DCR) of 90.9%, indicating strong efficacy, particularly among patients with low PD-L1 expression. The combination therapy demonstrated a favorable safety profile with minimal adverse effects.
Immutep Limited has announced the grant of two new patents for cancer treatment in Japan and South Korea. These patents protect combination therapies involving eftilagimod alpha (efti) and various chemotherapy agents, with an expiry date set for December 19, 2034. This follows the earlier grant of related patents across the US, Europe, China, and Australia. CEO Marc Voigt emphasized the importance of these patents in strengthening the company’s intellectual property and supporting the ongoing INSIGHT-003 clinical trial, with initial efficacy data expected at SITC 2022.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced its late-breaking abstract showcasing efficacy results for eftilagimod alpha in combination with pembrolizumab for non-small cell lung cancer (NSCLC) at the SITC 2022 Annual Meeting. Selected from over 1,500 submissions, it will be presented on November 8, 2022. A webcast on November 10, 2022, will discuss the abstract and Company updates. Additional data from the TACTI-002 Phase II trial will also be presented, with implications for ongoing and future cancer therapies.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) will present new clinical data for eftilagimod alpha in combination with pembrolizumab at the SITC Annual Meeting 2022. The oral presentation, scheduled for November 10, 2022, will focus on the TACTI-002 Phase II trial results involving 1st line non-small cell lung cancer (NSCLC) patients. Efti acts as an APC activator, aiming to enhance immune responses. The meeting will take place in Boston and virtually from November 8-12, 2022, with further details on the presentations to be available online.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced its CEO, Marc Voigt, will present at two investor conferences. The Bell Potter Healthcare Conference is scheduled for November 9, 2022, from 10:00am – 10:30am AEDT, followed by the 13th Annual Jefferies London Healthcare Conference on November 17, 2022, from 1:30pm – 2pm UTC. A live webcast of the Jefferies conference will be available on the company's website. Immutep focuses on developing LAG-3 immunotherapies for cancer and autoimmune diseases.
Immutep Limited has announced positive progress in its Phase IIb TACTI-003 trial, with the Independent Data Monitoring Committee recommending the continuation of the trial with no modifications. The trial evaluates eftilagimod alpha in combination with KEYTRUDA® for treating head and neck squamous cell carcinoma. Currently, 34% of the 154 patients have been recruited, and the FDA has granted Fast Track designation for this combination therapy, facilitating quicker clinical development and potential approval.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced its clinical development strategy focusing on eftilagimod alpha (efti) for treating non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), and metastatic breast cancer (MBC). Positive interim data from the TACTI-002 trial in NSCLC showed favorable results compared to standard chemotherapy. Additionally, the FDA granted Fast Track designation for efti in 1st line NSCLC. The company holds a strong cash position of $73.9 million, extending its financial runway into early 2024.
Immutep will present initial data from its INSIGHT-003 clinical trial at the upcoming SITC Annual Meeting 2022 in Boston from November 8-12. The trial evaluates the safety and efficacy of eftilagimod alpha combined with chemotherapy and anti-PD-1 therapy in patients with non-small-cell lung cancer (NSCLC) adenocarcinomas. A poster presentation will be held on November 11, with a focus on a cohort of 20 patients. Additionally, Immutep will present a TACTI-003 trial progress poster on November 10. The company aims to advance its innovative cancer treatments.
Immutep Limited (NASDAQ: IMMP) has announced that the US FDA granted Fast Track designation for eftilagimod alpha (efti) in combination with pembrolizumab for treating 1st line non-small cell lung cancer (NSCLC). This follows encouraging Phase II clinical results presented at ASCO 2022. The designation facilitates the expedited development and review process, allowing more frequent communication with the FDA. This is the second Fast Track designation for efti, which highlights its potential as a novel, chemotherapy-free treatment option for NSCLC patients.
FAQ
What is the current stock price of Immutep (IMMP)?
What is the market cap of Immutep (IMMP)?
What is the core focus of Immutep Ltd?
How does Immutep utilize LAG-3 technology in its treatments?
What are the key products in Immutep’s development pipeline?
In what ways does Immutep engage in global operations?
How do Immutep’s strategic partnerships influence its business model?
What role do research tax incentives play in Immutep’s operations?
How does Immutep maintain its expertise and trustworthiness in the biotech industry?
